[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

KR960705837A - 비포스포네이트 뉴클레오시드간 연결기와 혼합된 비대칭적으로 순수한 포스포네이트 뉴클레오시드간 연결기를 갖는 합성 올리고머(Synthetic Oligomers Having Chirally Pure Phosphonate Internucleosidyl Linkages Mixed with Non-Phosphonate Internucleosidyl Linkages) - Google Patents

비포스포네이트 뉴클레오시드간 연결기와 혼합된 비대칭적으로 순수한 포스포네이트 뉴클레오시드간 연결기를 갖는 합성 올리고머(Synthetic Oligomers Having Chirally Pure Phosphonate Internucleosidyl Linkages Mixed with Non-Phosphonate Internucleosidyl Linkages)

Info

Publication number
KR960705837A
KR960705837A KR1019960702553A KR19960702553A KR960705837A KR 960705837 A KR960705837 A KR 960705837A KR 1019960702553 A KR1019960702553 A KR 1019960702553A KR 19960702553 A KR19960702553 A KR 19960702553A KR 960705837 A KR960705837 A KR 960705837A
Authority
KR
South Korea
Prior art keywords
phosphonate
linker
group
carbon atoms
internucleoside
Prior art date
Application number
KR1019960702553A
Other languages
English (en)
Inventor
라일 죤. 2세 아놀드
리챠드 이사이스 호그레페
마크 알란 레이놀즈
티모시 앤드류 라일리
아론 슈와쯔 데이비드
모르테자 모니르 바제피
봅 데일 브라운
Original Assignee
라이오넬 엔. 사이몬
젠타 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 라이오넬 엔. 사이몬, 젠타 인코포레이티드 filed Critical 라이오넬 엔. 사이몬
Publication of KR960705837A publication Critical patent/KR960705837A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

본 발명은 RNA 타겟 서열에 대해 하이브리드화시키는, 비포스포네이트 뉴클레오시드간 연결기와 혼합된 비대칭적으로 순수한 포스포네이트 뉴클레오시드간 연결기를 갖는 올리고머 및 이의 제조방법이 제공된다.

Description

비포스포네이트 뉴클레오시드간 연결기와 혼합된 비대칭적으로 순수한 포스포네이트 뉴클레오시드간 연결기를 갖는 합성 올리고머(Systhetic Oligomers Having Chirally Pure Phosphonate Internucleosidyl Linkages Mixed with Non-Phosphonate Internucleosidyl Linkages)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (20)

  1. (a) 단일사 RNA 타겟을 서열을 확인하는 단계; 및 (b) 저급 알킬- 또는 아릴포스포네이트 뉴클레오시드간 연결기 및 비포스포네이트 뉴클레오시드간 연결기와 혼합된 저급 알킬- 또는 아릴포스포네이트 뉴클레오시드간 연결기로 이루어진 군으로부터 선택된 비대칭적으로 순수한 포스포네이트 뉴클레오시드간 연결기를 갖는 것으로, 여기서 비대칭적으로 순수한 포스포네이트 연결기는 단일 비포스포네이트 뉴클레오시드간 연결기 사이에 비포스포네이트 연결기 1대 포스포네이트 연결기 약 1내지 비포스포네이트 연결기 1대 포스포네이트 연결기 약 4의 비율로 산재되어 있으며, 올리고머는 상기 확인된 RNA 타겟 서열에 대해 실질적으로 상보적인 합성 올리고머를 합성하는 단계를 포함하는, RNA 타겟 서열에 대해 하이브리드화시키는 합성 올리고머의 제조 방법.
  2. 제1항에 있어서, 상기 비대칭적으로 순수한 포스포네이트 연결기가 알킬기의 탄소수가 1 내지 3인 Rp저급 알킬포스포네이트 연결기인 방법.
  3. 제2항에 있어서, 상기 Rp 저급 알킬포스포네이트 연결기가 Rp 메틸포스포네이트 연결기인 방법.
  4. 제3항에 있어서, 상기 비포스포네이트 연결기 대 포스포네이트 연결기가 비가 1대 약 1 내지 1대 약 3인 방법.
  5. 제3항에 있어서, 상기 올리고머의 뉴클레오시드가 당 잔기로서 탄소수 1 내지 10의 2′-O-알킬리보실, 2′-할로-리보실, 탄소수 3 내지 6의 2′-O-알케닐 리보실 및 2′-데옥시리보실로 이루어진 군으로부터 선택된 2′-치환된 리보실기를 갖는 방법.
  6. 제1항에 있어서, 상기 비포스포네이트 연결기가 포스포디에스테르, 포스포트리에스테르, 포스포로티오에이트, 포스포로디티오에이트, 포르포르아미데이트, 포스포로플루오리데이트, 보라노포스페이트, 포름아세탈 및 실릴로 이루어진 군으로부터 선택되는 방법.
  7. 제1항에 있어서, 다음식의 비대칭적으로 순수한 뉴클레오시드 이량체를 함께 연결시켜 상기 올리고머를 합성하는 방법.
    상기 식에서 X는 산소 또는 황이고; R은 탄소수 1 내지 3의 알킬이고; Z는 수소, 탄소수 1내지 10의 알콕시, 할로겐 또는 탄소수 3 내지 6의 알케닐옥시이고; B는 서로 독립적으로 선택되고 임의로 보호된 푸린 또는 피리미딘 염기이고; B1은 차단기이고; Cp는 커플링기이다.
  8. 제7항에 있어서, X가 산소이고 R이 메틸인 방법.
  9. 제8항에 있어서, 비대칭적으로 순수한 포스포네이트 연결기가 Rp 배위인 방법.
  10. 제9항에 있어서, Z가 수소 또는 메톡시인 방법.
  11. 제10항에 있어서, 비포스포네이트 연결기가 포르포디에스테르 연결기인 방법.
  12. 제11항에 있어서, Z가 메톡시인 방법.
  13. 저급 알킬- 또는 아릴포스포네이트 뉴클레오시드간 연결기 및 비포스포네이트 뉴클레오시드간 연결기와 혼합된 저급 알킬- 또는 아릴포스포네이트 뉴클레오시드간 연결기로 이루어진 군으로부터 선택된 비대칭적으로 순수한 포스포네이트 뉴클레오시드간 연결기를 갖는 것으로서, 여기서 비대칭적으로 순수한 포스포네이트 연결기는 단일 비포스포네이트 뉴클레오시드간 연결기사이에 비포스포네이트 연결기 1대 포스포네이트 연결기 약 1 내지 비포스포네이트 연결기 1대 포스포네이트 연결기 약 4의 비율로 산재되어 있으며, 올리고머는 RNA 타겟 서열에 대해 실질적으로 상보적인, 단일사 RNA 타겟 서열의 발현을 방지하거나 방해하는 활성을 갖는 합성 올리고머.
  14. 제13항에 있어서, 상기 포스포네이트 연결기가 비대칭적으로 순수한 Rp 메틸포스포네이트 연결기인 올리고머.
  15. 제14항에 있어서, 상기 비포스포네이트 연결기가 포스포디에스테르, 포스포트리에스테르, 포스포로티오에이트, 포스포로디티오에이트, 포르포르아미데이트, 포스포로플루오리데이트, 보라노포스페이트, 포름아세탈 및 실릴로 이루어진 군으로부터 선택된 올리고머.
  16. 제15항에 있어서, 상기 올리고머의 뉴클레오시드가 당 잔기로서 2′-O-메틸 리보실기를 갖는 올리고며,
  17. 탄소수 1 내지 3의 저급 알킬 포스포네이트 연결기 및 비포스포네이트 연결기와 혼합된, 탄소수 1 내지 3의 저급 알킬포스포노티오에이트 연결기로 이루어진 군으로부터 선택된 비댕칭적으로 수순한 포스포네이트 뉴클레오시드간 연결기를 갖는 올리고머로 이루어진 제제로, 올리고머는 단독 비포스포네이트 연결기 사이에 산재된 포스포네이트 연결기를 가지며, RNA 타겟 서열에 대해 상보적이고, 올리고머 제제는 상보적인 RNA 타겟 서열에 대한 “네트”결합 친화성이 향상된 것으로 입증된, 합성 올리고머 제제.
  18. 비대칭적으로 순수한 포스포네이트 뉴클레오시드간 연결기를 갖는 뉴클레오시드 이량체, 삼량체 또는 사량체를 함께 연결시키는 단계를 포함하는, 미리 결정된 염기 서열의 뉴클레오시드 유니트를 가지며 비포스포네이트 뉴클레오시드간 연결기와 혼합된 비대칭적으로 순수한 포스포네이트 뉴클레오시드간 연결기를 가지며 포스포네이트 뉴클레오시드간 연결기가 단독 비포스포네이트 뉴클레오시드간 연결기 사이에 산재되어 있는 올리고머의 제조 방법.
  19. 제18항에 있어서, 하기식의 비대칭적으로 순수한 신톤을 함께 연결하여 상기 올리고머를 합성하는 방법.
    상기 식에서 X는 산소 또는 황이고; R는 탄소수 1 내지 3의 알킬이고; Z는 수소, 탄소수 1 내지 10의 알콕시, 할로겐 또는 탄소수 3 내지 6의 알케닐옥시이고; B는 서로 독립적으로 선택되고 임의로 보호된 푸린 또는 피리미딘 염기이고; B1은 차단기이고; n은 1,2 또는 3이고; Cp는 커플링기이다.
  20. 다음식의 비대칭적으로 순수한 신톤.
    상기 식에서 X는 산소 또는 황이고; R은 탄소수 1 내지 3의 알킬이고; Z는 수소, 탄소수 1 내지 10의 알콕시, 할로겐 또는 탄소수 3내지 6의 알케닐옥시이고; B는 서로 독립적으로 선택되고 임의로 보호된 푸린 또는 피리미딘 염기이고; B1은 차단기이고; n은 1,2 또는 3이고; Cp는 커플링기이다.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019960702553A 1993-11-16 1994-11-16 비포스포네이트 뉴클레오시드간 연결기와 혼합된 비대칭적으로 순수한 포스포네이트 뉴클레오시드간 연결기를 갖는 합성 올리고머(Synthetic Oligomers Having Chirally Pure Phosphonate Internucleosidyl Linkages Mixed with Non-Phosphonate Internucleosidyl Linkages) KR960705837A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15401493A 1993-11-16 1993-11-16
US08/154,014 1993-11-16
PCT/US1994/013341 WO1995014030A1 (en) 1993-11-16 1994-11-16 Synthetic oligomers having chirally pure phosphonate internucleosidyl linkages mixed with non-phosphonate internucleosidyl linkages

Publications (1)

Publication Number Publication Date
KR960705837A true KR960705837A (ko) 1996-11-08

Family

ID=22549662

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019960702553A KR960705837A (ko) 1993-11-16 1994-11-16 비포스포네이트 뉴클레오시드간 연결기와 혼합된 비대칭적으로 순수한 포스포네이트 뉴클레오시드간 연결기를 갖는 합성 올리고머(Synthetic Oligomers Having Chirally Pure Phosphonate Internucleosidyl Linkages Mixed with Non-Phosphonate Internucleosidyl Linkages)

Country Status (9)

Country Link
US (2) US6028188A (ko)
EP (1) EP0729474A4 (ko)
JP (1) JPH09507836A (ko)
KR (1) KR960705837A (ko)
AU (1) AU678085B2 (ko)
CA (1) CA2176256A1 (ko)
IL (1) IL111659A0 (ko)
NZ (1) NZ276956A (ko)
WO (1) WO1995014030A1 (ko)

Families Citing this family (176)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050042647A1 (en) * 1996-06-06 2005-02-24 Baker Brenda F. Phosphorous-linked oligomeric compounds and their use in gene modulation
US7812149B2 (en) * 1996-06-06 2010-10-12 Isis Pharmaceuticals, Inc. 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
US20050053976A1 (en) * 1996-06-06 2005-03-10 Baker Brenda F. Chimeric oligomeric compounds and their use in gene modulation
US20050119470A1 (en) * 1996-06-06 2005-06-02 Muthiah Manoharan Conjugated oligomeric compounds and their use in gene modulation
US5898031A (en) * 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US20040147022A1 (en) * 1996-06-06 2004-07-29 Baker Brenda F. 2'-methoxy substituted oligomeric compounds and compositions for use in gene modulations
US20040171028A1 (en) * 1996-06-06 2004-09-02 Baker Brenda F. Phosphorous-linked oligomeric compounds and their use in gene modulation
US20040171031A1 (en) * 1996-06-06 2004-09-02 Baker Brenda F. Sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
US9096636B2 (en) 1996-06-06 2015-08-04 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds and their use in gene modulation
US20040203024A1 (en) * 1996-06-06 2004-10-14 Baker Brenda F. Modified oligonucleotides for use in RNA interference
US6096899A (en) * 1998-04-14 2000-08-01 The Regents Of The University Of Michigan Cylic imidazole compounds having relatively low hydrogen content and relatively high nitrogen content and polymers formed therefrom
EP1093373A4 (en) * 1998-07-02 2005-04-13 Univ Columbia OLIGONUCLEOTIDES INHIBITORS OF bcl-xL
CA2365901A1 (en) * 1999-04-14 2000-10-19 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
US7102024B1 (en) 2000-08-01 2006-09-05 Schwartz David A Functional biopolymer modification reagents and uses thereof
AU2001247697B2 (en) * 2000-03-22 2006-06-22 Solulink, Incorporated Hydrazine-based and carbonyl-based bifunctional crosslinking reagents
US6686461B1 (en) * 2000-03-22 2004-02-03 Solulink Bioscience, Inc. Triphosphate oligonucleotide modification reagents and uses thereof
US6773885B1 (en) * 2000-09-29 2004-08-10 Integrated Dna Technologies, Inc. Compositions and methods for visual ribonuclease detection assays
ES2409080T3 (es) * 2001-01-22 2013-06-24 Sangamo Biosciences Inc. Proteínas de unión con dedos de zinc modificadas
CA2491034A1 (en) * 2002-06-26 2004-01-08 The Penn State Research Foundation Methods and materials for treating human papillomavirus infections
WO2004044139A2 (en) * 2002-11-05 2004-05-27 Isis Parmaceuticals, Inc. Modified oligonucleotides for use in rna interference
WO2005044976A2 (en) * 2003-06-20 2005-05-19 Isis Pharmaceuticals, Inc. Oligomeric compounds for use in gene modulation
US7158353B2 (en) * 2003-11-06 2007-01-02 Seagate Technology Llc Magnetoresistive sensor having specular sidewall layers
US8569474B2 (en) * 2004-03-09 2013-10-29 Isis Pharmaceuticals, Inc. Double stranded constructs comprising one or more short strands hybridized to a longer strand
US8394947B2 (en) * 2004-06-03 2013-03-12 Isis Pharmaceuticals, Inc. Positionally modified siRNA constructs
JP2008501693A (ja) * 2004-06-03 2008-01-24 アイシス ファーマシューティカルズ、インク． 遺伝子調節で使用するための個別に調節された鎖を有する二本鎖組成物
US7884086B2 (en) * 2004-09-08 2011-02-08 Isis Pharmaceuticals, Inc. Conjugates for use in hepatocyte free uptake assays
CA2792561C (en) 2010-04-06 2021-10-26 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of cd274/pd-l1 gene
CA3102008A1 (en) 2010-06-02 2011-12-08 Alnylam Pharmaceuticals, Inc. Compositions and methods directed to treating liver fibrosis
EP2649182A4 (en) 2010-12-10 2015-05-06 Alnylam Pharmaceuticals Inc COMPOSITIONS AND METHOD FOR INCREASING AN ERYTHROPOIETIN (EPO) PREPARATION
WO2012079046A2 (en) 2010-12-10 2012-06-14 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of klf-1 and bcl11a genes
SG10201602369PA (en) 2011-03-29 2016-05-30 Alnylam Pharmaceuticals Inc Double-Stranded RNA (dsRNA) For Inhibiting Expression Of TMPRSS6
JP2014511694A (ja) 2011-04-03 2014-05-19 ザ ジェネラル ホスピタル コーポレーション ドゥーイング ビジネス アズ マサチューセッツ ジェネラル ホスピタル 修飾型ｒｎａ（ｍｏｄ−ｒｎａ）を使用する効率的なインビボタンパク質発現
CN103890000B (zh) 2011-06-21 2017-09-01 阿尔尼拉姆医药品有限公司 血管生成素样3(ANGPTL3)iRNA组合物及其使用方法
WO2012178033A2 (en) 2011-06-23 2012-12-27 Alnylam Pharmaceuticals, Inc. Serpina1 sirnas: compositions of matter and methods of treatment
US20140328811A1 (en) 2011-08-01 2014-11-06 Alnylam Pharmaceuticals, Inc. Method for improving the success rate of hematopoietic stem cell transplants
DK2742135T4 (da) * 2011-08-11 2020-07-13 Ionis Pharmaceuticals Inc Bindingsmodificerede gapped oligomeriske forbindelser og anvendelser deraf
US9133461B2 (en) 2012-04-10 2015-09-15 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the ALAS1 gene
US9127274B2 (en) 2012-04-26 2015-09-08 Alnylam Pharmaceuticals, Inc. Serpinc1 iRNA compositions and methods of use thereof
WO2014071358A2 (en) 2012-11-05 2014-05-08 Foundation Medicine, Inc. Novel ntrk1 fusion molecules and uses thereof
EP2945652B1 (en) 2013-01-18 2021-07-07 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma
US20150366890A1 (en) 2013-02-25 2015-12-24 Trustees Of Boston University Compositions and methods for treating fungal infections
PT2970974T (pt) 2013-03-14 2017-11-29 Alnylam Pharmaceuticals Inc Composições de irna de componente do complemento c5 e métodos para a sua utilização
CN105518146B (zh) 2013-04-04 2022-07-15 哈佛学院校长同事会 利用CRISPR/Cas系统的基因组编辑的治疗性用途
CA2912826A1 (en) 2013-05-22 2014-11-27 Alnylam Pharmaceuticals, Inc. Serpina1 irna compositions and methods of use thereof
EA201592225A1 (ru) 2013-05-22 2016-04-29 Элнилэм Фармасьютикалз, Инк. КОМПОЗИЦИИ НА ОСНОВЕ iRNA TMPRSS6 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
WO2014197835A2 (en) 2013-06-06 2014-12-11 The General Hospital Corporation Methods and compositions for the treatment of cancer
WO2015050990A1 (en) 2013-10-02 2015-04-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the lect2 gene
DK3052628T3 (da) 2013-10-04 2020-06-02 Alnylam Pharmaceuticals Inc Sammensætninger og fremgangsmåder til inhibering af ekspression af alas1-genet
WO2015061091A1 (en) 2013-10-21 2015-04-30 The General Hospital Corporation Methods relating to circulating tumor cell clusters and the treatment of cancer
SG10201804960RA (en) 2013-12-12 2018-07-30 Alnylam Pharmaceuticals Inc Complement component irna compositions and methods of use thereof
AU2014364520B2 (en) 2013-12-20 2020-01-02 The General Hospital Corporation Methods and assays relating to circulating tumor cells
KR102389968B1 (ko) 2014-02-11 2022-04-25 알닐람 파마슈티칼스 인코포레이티드 케토헥소키나제(ＫＨＫ) ｉＲＮＡ 조성물 및 그의 사용 방법
WO2015175510A1 (en) 2014-05-12 2015-11-19 Alnylam Pharmaceuticals, Inc. Methods and compositions for treating a serpinc1-associated disorder
EP3739048A1 (en) 2014-05-22 2020-11-18 Alnylam Pharmaceuticals, Inc. Angiotensinogen (agt) irna compositions and methods of use thereof
EP3148564B1 (en) 2014-06-02 2020-01-08 Children's Medical Center Corporation Methods and compositions for immunomodulation
EP3185910A4 (en) 2014-08-29 2018-01-10 Children's Medical Center Corporation Methods and compositions for the treatment of cancer
EP3191591A1 (en) 2014-09-12 2017-07-19 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting complement component c5 and methods of use thereof
JOP20200115A1 (ar) 2014-10-10 2017-06-16 Alnylam Pharmaceuticals Inc تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات))
WO2016061487A1 (en) 2014-10-17 2016-04-21 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof
WO2016069694A2 (en) 2014-10-30 2016-05-06 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting serpinc1 (at3) and methods of use thereof
JOP20200092A1 (ar) 2014-11-10 2017-06-16 Alnylam Pharmaceuticals Inc تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها
EP3221451A1 (en) 2014-11-17 2017-09-27 Alnylam Pharmaceuticals, Inc. Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof
EP3256587A2 (en) 2015-02-13 2017-12-20 Alnylam Pharmaceuticals, Inc. Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
EP4269601A3 (en) 2015-03-27 2024-01-10 President and Fellows of Harvard College Modified t cells and methods of making and using the same
US10745702B2 (en) 2015-04-08 2020-08-18 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the LECT2 gene
WO2016201301A1 (en) 2015-06-12 2016-12-15 Alnylam Pharmaceuticals, Inc. Complement component c5 irna compositions and methods of use thereof
EP3310918B1 (en) 2015-06-18 2020-08-05 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof
WO2016209862A1 (en) 2015-06-23 2016-12-29 Alnylam Pharmaceuticals, Inc. Glucokinase (gck) irna compositions and methods of use thereof
US10494632B2 (en) 2015-07-10 2019-12-03 Alnylam Pharmaceuticals, Inc. Insulin-like growth factor binding protein, acid labile subunit (IGFALS) compositions and methods of use thereof
MA43072A (fr) 2015-07-22 2018-05-30 Wave Life Sciences Ltd Compositions d'oligonucléotides et procédés associés
CN108368507B (zh) 2015-09-02 2022-03-22 阿尔尼拉姆医药品有限公司 程序性细胞死亡1配体1(PD-L1)的iRNA组合物及其使用方法
EP4424828A1 (en) 2015-12-07 2024-09-04 Genzyme Corporation Methods and compositions for treating a serpinc1-associated disorder
MA45295A (fr) 2016-04-19 2019-02-27 Alnylam Pharmaceuticals Inc Composition d'arni de protéine de liaison de lipoprotéines haute densité (hdlbp/vigiline) et procédés pour les utiliser
MA45270A (fr) 2016-05-04 2017-11-09 Wave Life Sciences Ltd Compositions d'oligonucléotides et procédés associés
JP2019518028A (ja) 2016-06-10 2019-06-27 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 補体成分Ｃ５ｉＲＮＡ組成物及び発作性夜間血色素尿症（ＰＮＨ）を処置するためのその使用方法
AU2017376950B2 (en) 2016-12-16 2024-02-22 Alnylam Pharmaceuticals, Inc. Methods for treating or preventing TTR-associated diseases using transthyretin (TTR) iRNA compositions
CN118384268A (zh) 2017-04-18 2024-07-26 阿尔尼拉姆医药品有限公司 具有乙肝病毒（hbv）感染的受试者的治疗方法
JP7277432B2 (ja) 2017-07-13 2023-05-19 アルナイラム ファーマシューティカルズ， インコーポレイテッド 乳酸脱水素酵素Ａ（ＬＤＨＡ）ｉＲＮＡ組成物及びその使用方法
US11866701B2 (en) 2017-11-01 2024-01-09 Alnylam Pharmaceuticals, Inc. Complement component C3 iRNA compositions and methods of use thereof
EP3710587A1 (en) 2017-11-16 2020-09-23 Alnylam Pharmaceuticals, Inc. Kisspeptin 1 (kiss1) irna compositions and methods of use thereof
EP3714054A1 (en) 2017-11-20 2020-09-30 Alnylam Pharmaceuticals, Inc. Serum amyloid p component (apcs) irna compositions and methods of use thereof
JP2021508491A (ja) 2017-12-18 2021-03-11 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 高移動度グループボックス−１（ＨＭＧＢ１）ｉＲＮＡ組成物及びその使用方法
TWI851574B (zh) 2018-05-14 2024-08-11 美商阿尼拉製藥公司 血管收縮素原（ＡＧＴ）ｉＲＮＡ組成物及其使用方法
US11492623B2 (en) 2018-08-13 2022-11-08 Alnylam Pharmaceuticals, Inc. Hepatitis B virus (HBV) dsRNA agent compositions and methods of use thereof
EP3837367A1 (en) 2018-08-16 2021-06-23 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the lect2 gene
CN118667811A (zh) 2018-09-18 2024-09-20 阿尔尼拉姆医药品有限公司 己酮糖激酶(KHK)iRNA组合物及其使用方法
US10913951B2 (en) 2018-10-31 2021-02-09 University of Pittsburgh—of the Commonwealth System of Higher Education Silencing of HNF4A-P2 isoforms with siRNA to improve hepatocyte function in liver failure
US20220056455A1 (en) 2018-12-20 2022-02-24 Praxis Precision Medicines, Inc. Compositions and methods for the treatment of kcnt1 related disorders
EP3897672B1 (en) 2018-12-20 2023-08-09 VIR Biotechnology, Inc. Combination hbv therapy
JP2022517270A (ja) 2019-01-16 2022-03-07 ジェンザイム・コーポレーション Ｓｅｒｐｉｎｃ１ ｉＲＮＡ組成物およびその使用方法
BR112021014940A2 (pt) * 2019-02-01 2021-09-28 Wave Life Sciences Ltd. Oligonucleotídeo, composição de oligonucleotídeo quiralmente controlada, composição farmacêutica, e método de tratamento, prevenção, atraso de início e/ou diminuição da gravidade de pelo menos um sintoma de doença de huntington
US20220339256A1 (en) 2019-05-13 2022-10-27 Vir Biotechnology, Inc. Compositions and methods for treating hepatitis b virus (hbv) infection
EP4007812A1 (en) 2019-08-01 2022-06-08 Alnylam Pharmaceuticals, Inc. Serpin family f member 2 (serpinf2) irna compositions and methods of use thereof
EP4007811A2 (en) 2019-08-01 2022-06-08 Alnylam Pharmaceuticals, Inc. Carboxypeptidase b2 (cpb2) irna compositions and methods of use thereof
WO2021030522A1 (en) 2019-08-13 2021-02-18 Alnylam Pharmaceuticals, Inc. SMALL RIBOSOMAL PROTEIN SUBUNIT 25 (RPS25) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
EP4025694A1 (en) 2019-09-03 2022-07-13 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the lect2 gene
US20220389429A1 (en) 2019-10-04 2022-12-08 Alnylam Pharmaceuticals, Inc. Compositions and methods for silencing ugt1a1 gene expression
EP4045652A1 (en) 2019-10-18 2022-08-24 Alnylam Pharmaceuticals, Inc. Solute carrier family member irna compositions and methods of use thereof
BR112022007540A2 (pt) 2019-10-22 2022-07-12 Alnylam Pharmaceuticals Inc Composições de irna de componente complementar c3 e métodos de uso das mesmas
WO2021087036A1 (en) 2019-11-01 2021-05-06 Alnylam Pharmaceuticals, Inc. HUNTINGTIN (HTT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
WO2021087325A1 (en) 2019-11-01 2021-05-06 Alnylam Pharmaceuticals, Inc. Compositions and methods for silencing dnajb1-prkaca fusion gene expression
JP2023502038A (ja) 2019-11-13 2023-01-20 アルナイラム ファーマシューティカルズ， インコーポレイテッド アンギオテンシノーゲン（ａｇｔ）関連障害を処置するための方法および組成物
WO2021102373A1 (en) 2019-11-22 2021-05-27 Alnylam Pharmaceuticals, Inc. Ataxin3 (atxn3) rnai agent compositions and methods of use thereof
JP2023506181A (ja) 2019-12-13 2023-02-15 アルナイラム ファーマシューティカルズ， インコーポレイテッド ヒト第９染色体オープンリーディングフレーム７２（Ｃ９ＯＲＦ７２）ｉＲＮＡ剤組成物およびその使用方法
TW202138559A (zh) 2019-12-16 2021-10-16 美商阿尼拉製藥公司 含類ＰＡＴＡＴＩＮ磷脂酶結構域３（ＰＮＰＬＡ３）ｉＲＮＡ組成物及其使用方法
WO2021154941A1 (en) 2020-01-31 2021-08-05 Alnylam Pharmaceuticals, Inc. Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
US20230136787A1 (en) 2020-02-10 2023-05-04 Alnylam Pharmaceuticals, Inc. Compositions and methods for silencing vegf-a expression
JP2023514336A (ja) 2020-02-18 2023-04-05 アルナイラム ファーマシューティカルズ， インコーポレイテッド アポリポタンパク質Ｃ３（ＡＰＯＣ３）ｉＲＮＡ組成物およびその使用法
EP4114947A1 (en) 2020-03-05 2023-01-11 Alnylam Pharmaceuticals, Inc. Complement component c3 irna compositions and methods of use thereof for treating or preventing complement component c3-associated diseases
BR112022017822A2 (pt) 2020-03-06 2022-11-08 Alnylam Pharmaceuticals Inc Composições de irna de cetoexocinase (khk) e métodos de uso das mesmas
WO2021188611A1 (en) 2020-03-18 2021-09-23 Alnylam Pharmaceuticals, Inc. Compositions and methods for treating subjects having a heterozygous alanine-glyoxylate aminotransferase gene (agxt) variant
JP2023519274A (ja) 2020-03-26 2023-05-10 アルナイラム ファーマシューティカルズ， インコーポレイテッド コロナウイルスｉＲＮＡ組成物およびその使用方法
WO2021202443A2 (en) 2020-03-30 2021-10-07 Alnylam Pharmaceucticals, Inc. Compositions and methods for silencing dnajc15 gene expression
IL297121A (en) 2020-04-06 2022-12-01 Alnylam Pharmaceuticals Inc Compositions and methods for silencing myoc expression
WO2021206917A1 (en) 2020-04-07 2021-10-14 Alnylam Pharmaceuticals, Inc. ANGIOTENSIN-CONVERTING ENZYME 2 (ACE2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
MX2022012561A (es) 2020-04-07 2022-11-07 Alnylam Pharmaceuticals Inc Composiciones y metodos para silenciar la expresion de la subunidad alfa tipo ix dependiente del voltaje del canal de sodio (scn9a).
WO2021206922A1 (en) 2020-04-07 2021-10-14 Alnylam Pharmaceuticals, Inc. Transmembrane serine protease 2 (tmprss2) irna compositions and methods of use thereof
KR20230018377A (ko) 2020-04-27 2023-02-07 알닐람 파마슈티칼스 인코포레이티드 아포지질단백질 e (apoe) irna 제제 조성물 및 이의 사용 방법
MX2022013606A (es) 2020-04-30 2023-01-16 Alnylam Pharmaceuticals Inc Composiciones de ácido ribonucleico interferente (arni) del factor b de complemento (cfb) y métodos de uso de las mismas.
EP4150076A1 (en) 2020-05-15 2023-03-22 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of methyl-cpg binding protein 2 (mecp2)
WO2021231692A1 (en) 2020-05-15 2021-11-18 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of otoferlin (otof)
EP4150078A1 (en) 2020-05-15 2023-03-22 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of argininosuccinate lyase (asl)
EP4150077A1 (en) 2020-05-15 2023-03-22 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of transmembrane channel-like protein 1 (tmc1)
EP4150086A1 (en) 2020-05-15 2023-03-22 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of leucine rich repeat kinase 2 (lrrk2)
EP4150087A1 (en) 2020-05-15 2023-03-22 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of gap junction protein beta 2 (gjb2)
EP4150089A1 (en) 2020-05-15 2023-03-22 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of retinoschisin 1 (rs1)
WO2021231675A1 (en) 2020-05-15 2021-11-18 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of argininosuccinate synthetase (ass1)
US20230183707A1 (en) 2020-05-21 2023-06-15 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting marc1 gene expression
US20230203484A1 (en) 2020-05-22 2023-06-29 Wave Life Sciences Ltd. Double stranded oligonucleotide compositions and methods relating thereto
US11408000B2 (en) 2020-06-03 2022-08-09 Triplet Therapeutics, Inc. Oligonucleotides for the treatment of nucleotide repeat expansion disorders associated with MSH3 activity
EP4162050A1 (en) 2020-06-09 2023-04-12 Alnylam Pharmaceuticals, Inc. Rnai compositions and methods of use thereof for delivery by inhalation
AU2021292296A1 (en) 2020-06-18 2023-01-19 Alnylam Pharmaceuticals, Inc. Xanthine dehydrogenase (XDH) iRNA compositions and methods of use thereof
IL299201A (en) 2020-06-24 2023-02-01 Vir Biotechnology Inc Transgenic hepatitis B virus neutralizing antibodies and their uses
EP4217489A1 (en) 2020-09-24 2023-08-02 Alnylam Pharmaceuticals, Inc. Dipeptidyl peptidase 4 (dpp4) irna compositions and methods of use thereof
WO2022076291A1 (en) 2020-10-05 2022-04-14 Alnylam Pharmaceuticals, Inc. G protein-coupled receptor 75 (gpr75) irna compositions and methods of use thereof
WO2022087041A1 (en) 2020-10-21 2022-04-28 Alnylam Pharmaceuticals, Inc. Methods and compositions for treating primary hyperoxaluria
WO2022087329A1 (en) 2020-10-23 2022-04-28 Alnylam Pharmaceuticals, Inc. Mucin 5b (muc5b) irna compositions and methods of use thereof
EP4244355A1 (en) 2020-11-13 2023-09-20 Alnylam Pharmaceuticals, Inc. Coagulation factor v (f5) irna compositions and methods of use thereof
EP4256053A1 (en) 2020-12-01 2023-10-11 Alnylam Pharmaceuticals, Inc. Methods and compositions for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
EP4259795A1 (en) 2020-12-08 2023-10-18 Alnylam Pharmaceuticals, Inc. Coagulation factor x (f10) irna compositions and methods of use thereof
KR20230135585A (ko) 2020-12-23 2023-09-25 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 변형된 trem의 조성물 및 이의 용도
WO2022150260A1 (en) 2021-01-05 2022-07-14 Alnylam Pharmaceuticals, Inc. COMPLEMENT COMPONENT 9 (C9) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
IL304880A (en) 2021-02-12 2023-10-01 Alnylam Pharmaceuticals Inc Superoxide dismutase 1 (SOD1) IRNA compositions and methods of using them to treat or prevent superoxide dismutase 1- (SOD1-) associated neurodegenerative diseases
JP2024509783A (ja) 2021-02-25 2024-03-05 アルナイラム ファーマシューティカルズ， インコーポレイテッド プリオンタンパク質（ｐｒｎｐ）ｉｒｎａ組成物およびその使用方法
JP2024515423A (ja) 2021-02-26 2024-04-10 アルナイラム ファーマシューティカルズ， インコーポレイテッド ケトヘキソキナーゼ（ＫＨＫ）ｉＲＮＡ組成物およびその使用方法
TW202302849A (zh) 2021-03-04 2023-01-16 美商艾拉倫製藥股份有限公司 類血管生成素３（ＡＮＧＰＴＬ３）ｉＲＮＡ組成物及其使用方法
WO2022192519A1 (en) 2021-03-12 2022-09-15 Alnylam Pharmaceuticals, Inc. Glycogen synthase kinase 3 alpha (gsk3a) irna compositions and methods of use thereof
IL307239A (en) 2021-03-29 2023-11-01 Alnylam Pharmaceuticals Inc Preparations containing Huntingtin IRNA factor (HTT) and methods of using them
WO2022212153A1 (en) 2021-04-01 2022-10-06 Alnylam Pharmaceuticals, Inc. Proline dehydrogenase 2 (prodh2) irna compositions and methods of use thereof
BR112023022284A2 (pt) 2021-04-26 2023-12-26 Alnylam Pharmaceuticals Inc Composições de irna de protease transmembrana, serina 6 (tmprss6) e métodos de uso da mesma
JP2024519293A (ja) 2021-04-29 2024-05-10 アルナイラム ファーマシューティカルズ， インコーポレイテッド シグナル伝達兼転写活性化因子６（ＳＴＡＴ６）ｉＲＮＡ組成物およびその使用方法
EP4341401A1 (en) 2021-05-18 2024-03-27 Alnylam Pharmaceuticals, Inc. Sodium-glucose cotransporter-2 (sglt2) irna compositions and methods of use thereof
WO2022246023A1 (en) 2021-05-20 2022-11-24 Korro Bio, Inc. Methods and compositions for adar-mediated editing
WO2022256283A2 (en) 2021-06-01 2022-12-08 Korro Bio, Inc. Methods for restoring protein function using adar
TW202317762A (zh) 2021-06-02 2023-05-01 美商艾拉倫製藥股份有限公司 含有類ＰＡＴＡＴＩＮ磷脂酶結構域３（ＰＮＰＬＡ３）的ｉＲＮＡ組成物及其使用方法
KR20240017911A (ko) 2021-06-04 2024-02-08 알닐람 파마슈티칼스 인코포레이티드 인간 염색체 9 개방 해독 프레임 72(C9orf72) iRNA 제제 조성물 및 이의 사용 방법
WO2022260939A2 (en) 2021-06-08 2022-12-15 Alnylam Pharmaceuticals, Inc. Compositions and methods for treating or preventing stargardt's disease and/or retinal binding protein 4 (rbp4)-associated disorders
US20230194709A9 (en) 2021-06-29 2023-06-22 Seagate Technology Llc Range information detection using coherent pulse sets with selected waveform characteristics
WO2023278410A1 (en) 2021-06-29 2023-01-05 Korro Bio, Inc. Methods and compositions for adar-mediated editing
MX2023015489A (es) 2021-06-30 2024-01-19 Alnylam Pharmaceuticals Inc Metodos y composiciones para tratar un trastorno asociado al angiotensinogeno (agt).
EP4373934A1 (en) 2021-07-19 2024-05-29 Alnylam Pharmaceuticals, Inc. Methods and compositions for treating subjects having or at risk of developing a non-primary hyperoxaluria disease or disorder
IL309905A (en) 2021-07-23 2024-03-01 Alnylam Pharmaceuticals Inc IRNA compositions in β-catenin (CTNNB1) and methods of using them
WO2023009687A1 (en) 2021-07-29 2023-02-02 Alnylam Pharmaceuticals, Inc. 3-hydroxy-3-methylglutaryl-coa reductase (hmgcr) irna compositions and methods of use thereof
KR20240042004A (ko) 2021-08-03 2024-04-01 알닐람 파마슈티칼스 인코포레이티드 트랜스티레틴(TTR) iRNA 조성물 및 이의 사용 방법
IL310295A (en) 2021-08-04 2024-03-01 Alnylam Pharmaceuticals Inc iRNA compositions and methods for silencing angiotensinogen (AGT)
AR126771A1 (es) 2021-08-13 2023-11-15 Alnylam Pharmaceuticals Inc COMPOSICIONES DE ARNi CONTRA EL FACTOR XII (F12) Y SUS MÉTODOS DE USO
WO2023044370A2 (en) 2021-09-17 2023-03-23 Alnylam Pharmaceuticals, Inc. Irna compositions and methods for silencing complement component 3 (c3)
WO2023044094A1 (en) 2021-09-20 2023-03-23 Alnylam Pharmaceuticals, Inc. Inhibin subunit beta e (inhbe) modulator compositions and methods of use thereof
CA3234835A1 (en) 2021-10-22 2023-04-27 Korro Bio, Inc. Methods and compositions for disrupting nrf2-keap1 protein interaction by adar mediated rna editing
EP4423272A2 (en) 2021-10-29 2024-09-04 Alnylam Pharmaceuticals, Inc. Huntingtin (htt) irna agent compositions and methods of use thereof
KR20240095325A (ko) 2021-10-29 2024-06-25 알닐람 파마슈티칼스 인코포레이티드 보체 인자 b (cfb) irna 조성물 및 이의 사용 방법
WO2023141314A2 (en) 2022-01-24 2023-07-27 Alnylam Pharmaceuticals, Inc. Heparin sulfate biosynthesis pathway enzyme irna agent compositions and methods of use thereof
WO2024039776A2 (en) 2022-08-18 2024-02-22 Alnylam Pharmaceuticals, Inc. Universal non-targeting sirna compositions and methods of use thereof
TW202424193A (zh) 2022-09-15 2024-06-16 美商艾拉倫製藥股份有限公司 第１３型１７β－羥基類固醇去氫酶（ＨＳＤ１７Ｂ１３）ｉＲＮＡ組成物及其使用方法
WO2024168010A2 (en) 2023-02-09 2024-08-15 Alnylam Pharmaceuticals, Inc. Reversir molecules and methods of use thereof
WO2024220746A2 (en) 2023-04-21 2024-10-24 Flagship Pioneering Innovations Vii, Llc Rnai agents targeting fatty acid synthase and related methods

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4358535A (en) * 1980-12-08 1982-11-09 Board Of Regents Of The University Of Washington Specific DNA probes in diagnostic microbiology
US5403711A (en) * 1987-11-30 1995-04-04 University Of Iowa Research Foundation Nucleic acid hybridization and amplification method for detection of specific sequences in which a complementary labeled nucleic acid probe is cleaved
US5212295A (en) * 1990-01-11 1993-05-18 Isis Pharmaceuticals Monomers for preparation of oligonucleotides having chiral phosphorus linkages
NZ239250A (en) * 1990-08-09 1993-12-23 Genta Inc Chirally pure non-nucleotide reagents for use in preparing
DE69316369D1 (en) * 1992-07-27 1998-02-19 Hybridon Inc Oligonukleotid alkylphosphonothiate
US5457026A (en) * 1992-11-20 1995-10-10 University Of Pennsylvania Methods of promoting intermolecular interactions involving a nucleic acid

Also Published As

Publication number Publication date
WO1995014030A1 (en) 1995-05-26
JPH09507836A (ja) 1997-08-12
CA2176256A1 (en) 1995-05-26
IL111659A0 (en) 1995-01-24
AU678085B2 (en) 1997-05-15
AU1181995A (en) 1995-06-06
EP0729474A4 (en) 1998-10-21
US5792615A (en) 1998-08-11
EP0729474A1 (en) 1996-09-04
NZ276956A (en) 1998-04-27
US6028188A (en) 2000-02-22

Similar Documents

Publication Publication Date Title
KR960705837A (ko) 비포스포네이트 뉴클레오시드간 연결기와 혼합된 비대칭적으로 순수한 포스포네이트 뉴클레오시드간 연결기를 갖는 합성 올리고머(Synthetic Oligomers Having Chirally Pure Phosphonate Internucleosidyl Linkages Mixed with Non-Phosphonate Internucleosidyl Linkages)
JP2898750B2 (ja) 有機リン化合物をイオウ化するための方法およびそのための試薬
RU2227143C2 (ru) Новые бициклонуклеозидные аналоги
KR930702372A (ko) 유전자 발현 억제용 화합물 및 방법
Agrawal et al. Oligodeoxynucleoside methylphosphonates: synthesis and enzymic degradation
AU678769B2 (en) Oligonucleotide alkylphosphonothioates
Goodchild Conjugates of oligonucleotides and modified oligonucleotides: a review of their synthesis and properties
US5571902A (en) Synthesis of oligonucleotides
Lesnikowski et al. Nucleic acids and nucleosides containing carboranes
EP0698034A1 (fr) Oligonucleotides phosphorothioates triesters et procede de preparation
KR920701230A (ko) 엑소뉴클레아제-내성 올리고뉴클레오티드 및 그 제조방법
CA2168409A1 (en) G cap-stabilized oligonucleotides
JP3653102B2 (ja) 末端３′−３′および／または５′−５′連鎖を有するオリゴリボヌクレオチドおよびリボザイム類縁体
Guinosso et al. Synthesis and biophysical and biological evaluation of 2′-modified antisense oligonucleotides
KR900701813A (ko) 뉴클레오시드, 폴리뉴클레오티드 티오포스포르아미다이트 및 포스포로디티오에이트 화합물 및 그 제조방법
US5420330A (en) Lipo-phosphoramidites
KR960705589A (ko) 키메라형 올리고뉴클레오시드 화합물(Chimeric Oligonucleoside Compounds)
EP0711302B1 (en) Building blocks with carbamate internucleoside linkages and novel oligonucleotides derived therefrom
KR960700262A (ko) 이합체 블록의 합성 및 그것의 올리고누클레오티드 어셈블리에의 사용 방법(synthesis of dimmer blocks and their use in assembling oligonucleotides)
Fathi et al. (Aminomethyl) phosphonate derivatives of oligonucleotides
Matteucci Hybridization Properties of a DeoxyoIigonucleotide Containing Four Formacetal Linkages
AU642673B2 (en) Method and reagent for sulfurization of organophosphorous compounds
Debart et al. Optimization of hybridizing abilities and nuclease resistance in the design of chimeric α-anomeric oligodeoxynucleotides containing β-anomeric gaps
Habus et al. Synthesis of di-, tri-, and tetrameric building blocks with novel carbamate internucleoside linkages and their incorporation into oligonucleotides
KR970707144A (ko) 아미노산 핵산(amino acid nucleic acids)

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid